• Please log in or register to access this feature.

Prospects

You have free access to this content

Emerging molecular networks in Burkitt's lymphoma†

  1. Davide Mangani1,2,
  2. Annalisa Roberti1,
  3. Flavio Rizzolio1,3,
  4. Antonio Giordano1,4,*

Article first published online: 14 NOV 2012

DOI: 10.1002/jcb.24358

Issue

Journal of Cellular Biochemistry

Journal of Cellular Biochemistry

Volume 114, Issue 1, pages 35–38, January 2013

Additional Information

How to Cite

Mangani, D., Roberti, A., Rizzolio, F. and Giordano, A. (2013), Emerging molecular networks in Burkitt's lymphoma. J. Cell. Biochem., 114: 35–38. doi: 10.1002/jcb.24358

Author Information

  1. 1

    Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA

  2. 2

    Human Health Foundation, Terni and Spoleto (PG), Italy

  3. 3

    Experimental and Clinical Pharmacology - National Cancer Institute IRCCS Aviano, Italy

  4. 4

    Department of Human Pathology and Oncology, University of Siena, Siena, Italy

*Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, 1900N. 12th Street, Bio Life Sciences Building Suite 431, Philadelphia, PA 19122.

  1. †

    The authors declare no conflict of interest.

Publication History

  1. Issue published online: 14 NOV 2012
  2. Article first published online: 14 NOV 2012
  3. Accepted manuscript online: 17 AUG 2012 08:33AM EST
  4. Manuscript Accepted: 8 AUG 2012
  5. Manuscript Received: 26 JUL 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (63K)

REFERENCES

  • Basso K, Sumazin P, Morozov P, Schneider C, Maute RL, Kitagawa Y, Mandelbaum J, Haddad J, Jr., Chen C-Z, Califano A, Dalla-Favera R. 2009. Identification of the human mature B cell miRNome. Immunity 30:744–752.
  • Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. 2011. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 10:29–46.
  • Boerman OC, Oyen WJ, Corstens FH. 2000. Pretargeted radioimmunotherapy of non-Hodgkin's lymphoma: Best of both worlds? Cancer Biother Radiopharm 15(1):1–5.
  • De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, Onnis A, Cerino G, Nyagol J, Mwanda W, Bellan C, Hummel M, Pileri S, Tosi P, Stein H, Giordano A, Leoncini L. 2007. Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood 110:1301–1307.
  • De Falco G, Antonicelli G, Onnis A, Lazzi S, Bellan C, Leoncini L. 2009. Role of EBV in microRNA dysregulation in Burkitt lymphoma. Sem Cancer Biol 19:401–406.
  • El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
  • Ferry JA. Burkitt's lymphoma: Clinicopathologic features and differential diagnosis. Oncologist 2006. 11:375–383.
  • God JM, Haque A. 2010. Burkitt lymphoma: Pathogenesis and immune evasion. J Oncol. 2010: pii: 516047. Epub 2010 Oct 5.
  • Gromminger S, Mautner J, Bornkamm GW. 2012. Burkitt lymphoma: The role of Epstein–Barr virus revisited. Br J Haematol 156:719–729.
    Direct Link:
  • Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kuhn M, Lenze D, Lichter P, Martin-Subero JI, Moller P, Muller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Sturzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trumper L, Stein H, Siebert R. 2006. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419–2430.
  • Kempkes B, Spitkovsky D, Jansen-Dürr P, Ellwart JW, Kremmer E, Delecluse HJ, Rottenberger C, Bornkamm GW, Hammerschmidt W. 1995. B-cell proliferation and induction of early G1-regulating proteins by Epstein–Barr virus mutants conditional for EBNA2. EMBO J 14(1):88–96.
  • Kohlhof H, Hampel F, Hoffmann R, Burtscher H, Weidle UH, Hölzel M, Eick D, Zimber-Strobl U, Strobl LJ. 2009. Notch1, Notch2, and Epstein–Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein–Barr virus-infected B cells. Blood 113:5506–5515.
  • Kubbutat MHG, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299–303.
  • Kuppers R. 2003. B cells under influence: Transformation of B cells by Epstein–Barr virus. Nat Rev Immunol 3:801–812.
  • Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B, Lazzi S, Tosi P, van Krieken H, Leoncini L. 2008. MYC translocation-negative classical Burkitt lymphoma cases: An alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 216:440–450.
    Direct Link:
  • Lindstrom MS, Klangby U, Wiman KG. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001. 20:2171–2177.
  • Littlewood TD, Amati B, Land H, Evan GI. 1992. Max and c-Myc/Max DNA-binding activities in cell extracts. Oncogene 7:1783–1792.
  • Mani KM, Lefebvre C, Wang K, Lim WK, Basso K, Dalla-Favera R, Califano A. 2008. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol Syst Biol 4. 169.
  • Marbach D, Prill RJ, Schaffter T, Mattiussi C, Floreano D, Stolovitzky G. 2010. Revealing strengths and weaknesses of methods for gene network inference. Proc Natl Acad Sci USA 107:6286–6291.
  • Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, Takada K. 2006. Epstein–Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci USA 103:19500–19505.
  • McShane MP, Longnecker R. 2004. Cell-surface expression of a mutated Epstein–Barr virus glycoprotein B allows fusion independent of other viral proteins. Proc Natl Acad Sci USA 101:17474–17479.
  • Meyer N, Penn LZ. 2008. Reflecting on 25 years with MYC. Nat Rev Cancer 8:976–990.
  • Orsborne C, Byers R. 2011. Impact of gene expression profiling in lymphoma diagnosis and prognosis. Histopathology 58:106–127.
    Direct Link:
  • Rizzolio F, Esposito L, Muresu D, Fratamico R, Jaraha R, Caprioli GV, Giordano A. 2010. RB gene family: Genome-wide ChIP approaches could open undiscovered roads. J Cell Biochem 109:839–843.
  • Rizzolio F, Caligiuri I, Lucchetti C, Fratamico R, Tomei V, Gallo G, Agelan A, Ferrari G, Toffoli G, Klein-Szanto AJ, Giordano A. 2012a. Dissecting Pin1 and phospho-pRb regulation. J Cell Physiol. DOI: 10.1002/jcp.24107 [Epub ahead of print].
  • Rizzolio F, Lucchetti C, Caligiuri I, Marchesi I, Caputo M, Klein-Szanto AJ, Bagella L, Castronovo M, Giordano A. 2012b. Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1. Cell Death Differ. 19(7):1152–1161. DOI: 10.1038/cdd.2011.202. Epub 2012 Feb 10.
  • Roberti A, Rizzolio F, Lucchetti C, de Leval L, Giordano A. 2011. Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines. Cell Cycle 10:127–134.
  • Salaverria I, Siebert R. 2011. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 29:1835–1843.
  • Sinclair AJ, Palmero I, Peters G, Farrell PJ. 1994. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein–Barr virus. EMBO J 13(14):3321–3328.
  • Spear PG, Longnecker R. 2003. Herpesvirus entry: An update. J Virol 77:10179–10185.
  • Tao J, Wasik MA. 2001. Epstein–Barr virus associated polymorphic lymphoproliferative disorders occurring in nontransplant settings. Lab Invest 81:429–437.
  • Vennstrom B, Sheiness D, Zabielski J, Bishop JM. 1982. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 42:773–779.
  • Villuendas R, Sánchez-Beato M, Martínez JC, Saez AI, Martinez-Delgado B, García JF, Mateo MS, Sanchez-Verde L, Benítez J, Martínez P, Piris MA. 1998. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 153:887–897.
  • Zindy F. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424–2433.
View Full Article (HTML) Get PDF (63K)